AbCellera Biologics has patented a method for enhancing immunoglobulin diversity by isolating B cells from genetically modified mice. The invention allows for the production of antibodies that have not been subjected to selection by tolerance mechanisms, leading to a broader repertoire of antibodies. GlobalData’s report on AbCellera Biologics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights AbCellera Biologics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AbCellera Biologics, Molecular diagnosis biomarkers was a key innovation area identified from patents. AbCellera Biologics's grant share as of February 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

Enhanced production of diverse antibodies using genetically modified mice

Source: United States Patent and Trademark Office (USPTO). Credit: AbCellera Biologics Inc

A recently granted patent (Publication Number: US11889821B2) discloses a method for isolating primary B cells, immortalized B cells, or hybridomas derived from a genetically modified mouse. The genetically modified mouse's genome contains specific immunoglobulin heavy chain alleles that allow for the expression of functional immunoglobulin heavy chains while also enabling site-specific recombination to correct deficiencies in the expression of a second immunoglobulin heavy chain allele. This correction facilitates the production of a functional immunoglobulin heavy chain without being subjected to selection by tolerance mechanisms.

Furthermore, the patent claims detail modifications to the second immunoglobulin heavy chain allele to disable in-frame VDJ rearrangement for allelic exclusion but preserve it for inducible expression. The method described in the patent allows for the efficient expression of a functional heavy chain from the second immunoglobulin heavy chain allele at various stages of B cell development, including induction following the presence of specific recombinases, DNA-modifying proteins, or transcriptional regulators. Additionally, the patent covers the use of inducible promoters derived from genes expressed after B cells have matured, such as CD21 or CD23, to control the expression of site-specific recombinases for switching CH functionality between the first and second immunoglobulin heavy chain alleles.

To know more about GlobalData’s detailed insights on AbCellera Biologics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies